1. Home
  2. WKHS vs INKT Comparison

WKHS vs INKT Comparison

Compare WKHS & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Workhorse Group Inc.

WKHS

Workhorse Group Inc.

HOLD

Current Price

$2.92

Market Cap

33.7M

ML Signal

HOLD

Logo MiNK Therapeutics Inc.

INKT

MiNK Therapeutics Inc.

HOLD

Current Price

$11.71

Market Cap

59.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WKHS
INKT
Founded
2007
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Auto Manufacturing
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
33.7M
59.4M
IPO Year
2008
2021

Fundamental Metrics

Financial Performance
Metric
WKHS
INKT
Price
$2.92
$11.71
Analyst Decision
Hold
Buy
Analyst Count
1
2
Target Price
$21.00
$35.00
AVG Volume (30 Days)
89.1K
11.5K
Earning Date
05-14-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
86.92
N/A
EPS
N/A
N/A
Revenue
$763,173.00
N/A
Revenue This Year
$89.23
N/A
Revenue Next Year
$28.84
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.53
$8.48
52 Week High
$11.80
$16.80

Technical Indicators

Market Signals
Indicator
WKHS
INKT
Relative Strength Index (RSI) 43.31 52.38
Support Level $2.84 $10.82
Resistance Level $3.51 $12.04
Average True Range (ATR) 0.23 0.52
MACD -0.03 -0.01
Stochastic Oscillator 2.60 47.06

Price Performance

Historical Comparison
WKHS
INKT

About WKHS Workhorse Group Inc.

Workhorse Group Inc is a technology company with a vision to pioneer the transition to zero-emission commercial vehicles. Its focus is to provide sustainable and cost-effective solutions to the commercial transportation sector. It designs and manufactures all-electric vehicles, including the technology that optimizes the way these vehicles operate. It's focused on a core competency of bringing electric delivery vehicle platforms to serve the last-mile delivery market. Its products are marketed under the Workhorse brand.

About INKT MiNK Therapeutics Inc.

MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.

Share on Social Networks: